logo
logo
MXCT stock ticker logo

MaxCyte, Inc.

NASDAQ•MXCT
執行長: Mr. Maher Masoud
板塊: Healthcare
行業: Medical - Devices
上市日期: 2021-07-30
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
聯絡資訊
9713 Key West Avenue, Suite 400, Rockville, MD, 20850, United States
301-944-1700
www.maxcyte.com
市值
$87.45M
本益比 (TTM)
-1.9
26.6
股息率
--
52周最高
$3.33
52周最低
$0.64
52周範圍
7%
排名55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
疲弱 • 2.6 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025

財務儀表板

Q3 2025 數據

營業收入

$6.83M-16.35%
近4季度走勢

每股收益

-$0.12+9.09%
近4季度走勢

自由現金流

-$7.76M+61.73%
近4季度走勢

2025 Q3 財報亮點

核心亮點

Q3 Revenue Decline Total revenue $6.83M USD for Q3 2025, a 16% decrease versus Q3 2024, driven primarily by core sales contraction.
SPL Revenue Volatility Nine months SPL program revenue $2.88M USD, falling 52% due to uncertain achievement timing of clinical milestones.
SeQure Acquisition Finalized Acquired SeQure in January 2025; preliminary goodwill recorded at $3.55M USD following purchase price allocation adjustments.
Increased Operating Burn Net cash used in operating activities totaled $31.72M USD for nine months, significantly higher than the prior year period.

關注風險

Widening Net Loss Nine months net loss reached $(35.03M) USD, increasing from $(30.46M) USD in 2024 due to lower revenue.
Cash Position Decline Cash and equivalents decreased to $12.97M USD by September 30, 2025, reflecting increased operating cash burn.
Restructuring Execution Costs Implemented 34% workforce reduction plan, incurring $3.06M USD restructuring expense during the third quarter period.
Customer Concentration Risk One customer accounted for 51% of total accounts receivable as of September 30, 2025, posing significant concentration risk.

未來展望

Liquidity Runway Secured Existing cash resources expected to fund operating expenses and capital needs for at least the next 12 months.
Strategic Cost Alignment Workforce reduction plan targets 34% reduction to streamline operations and align resources with strategic priorities.
Future Revenue Expectation Expect total revenue growth as customer programs advance, driven by instrument sales and expanding SPL base.
Continued R&D Investment Expect substantial research and development expenses to support customers and develop new product offerings going forward.

同行對比

營業收入 (TTM)

ATLN stock ticker logoATLN
$445.38M
+3.8%
OWLT stock ticker logoOWLT
$105.66M
+35.3%
PRE stock ticker logoPRE
$95.11M
+210.6%

毛利率 (最新季度)

SGMO stock ticker logoSGMO
100.0%
+0.0pp
MXCT stock ticker logoMXCT
92.4%
+16.1pp
SGHT stock ticker logoSGHT
87.3%
+2.5pp

關鍵指標

股票代碼
市值
本益比 (TTM)
股東權益報酬率 (TTM)
負債率
ARMP$383.73M-8.170.3%198.5%
CATX$371.61M-3.5-39.1%1.1%
FBRX$334.97M-9.2-75.6%0.0%

長期趨勢

近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
-7.7%
增長承壓
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
0%
現金流需要關注

深度研究

下次財報:2026年3月24日
|
每股收益:-$0.08
|
營業收入:$9.16M
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表
過去12個月
無資料